Whitehawk Therapeutics Divests Aadi Subsidiary to Kaken Pharmaceuticals

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

October 10, 2025

Pharmaceuticals

Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.

Supreme Group Acquires Kadiko

March 5, 2025

Marketing & Advertising

Supreme Group, a Trinity Hunt-backed platform for life sciences and healthcare marketing, has acquired Kadiko, a San Francisco–based digital-first brand strategy and creative agency. The add-on expands Supreme Group's AI-enhanced insights, digital and brand strategy capabilities to better serve healthcare and life sciences clients.

MedEdge Holdings Formed Through $450 Million Management-Led Buyout of Abyrx and Kairuku

November 24, 2025

Medical Devices

Abyrx, Inc. and Kairuku, Inc. completed a combined $450 million management-led buyout and capital raise to form MedEdge Holdings LLC. The new holding company will integrate Abyrx's biosurgical product portfolio with Kairuku's SaaS commercial operations platform and deploy capital to acquire 10–15 commercial-stage surgical product companies to accelerate growth and streamline product delivery to operating rooms.

Advent International to Acquire Significant Stake in Suven Pharmaceuticals

December 26, 2022

Pharmaceuticals

Advent International has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family and will make an open offer for an additional 26% of public shares. Advent plans to evaluate a merger of its CDMO and API platform company, Cohance Lifesciences, with Suven to create a scaled end-to-end CDMO + merchant API powerhouse serving pharma and specialty chemical markets, subject to board and regulatory approvals.

CVC Acquires Therakos Business from Mallinckrodt for $925M

August 5, 2024

Medical Devices

CVC Capital Partners Fund IX agreed to acquire the Therakos extracorporeal photopheresis business from Mallinckrodt plc for $925 million in a carve-out transaction. CVC said it will invest in further research, indication expansion and geographic growth of Therakos while key Therakos employees will transition with the business; Mallinckrodt will use proceeds to substantially reduce net debt.

Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M

May 1, 2020

Medical Devices

Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.